Vaccine Therapies

Adjuvant autologous renal tumour cell vaccine and the risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Author: Jocham D, et al. Source: Lancet, 363, Feb 2004, pg 594 Background Over 31,000 new cases of renal cell carcinoma are expected in the United States this year Approximately 75% of renal cell carcinomas are local or regional upon...
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group (SWOG-9035) Authors: Vernon K. Sondak, P.-Y. Liu, Ralph J. Tuthill, Raymond A. Kempf, Joseph M. Unger, Jeffrey A. Sosman, John A. Thompson, Geoffrey R. Weiss, Bruce G. Redman, James G. Jakowatz, R. Dirk Noyes, and Lawrence E. Flaherty Source: Journal of...
Amplification of Virus-Induced Antimelanoma T-Cell Reactivity by High-Dose Interferon- a2b: Implications for Cancer Vaccines Authors: Astsaturov I, et al. Source: Clinical Cancer Research, 9, 2003, pg 4347 Background A number of tumor antigens have been identified in melanoma and other cancers. These have been used to make specific cancer vaccines Current...
Cancer Vaccines: Between the Idea and the Reality Author: Finn, OL Source: Nature Reviews-Immunology, August 2003, pg 630 This is an excellent review article illustrating the current state of cancer vaccines and the hurdles that must be overcome if vaccines are to make their way into the clinic....
Current Developments in Cancer Vaccines and Cellular Immunotherapy Author: Ribas A, Butterfield LH, Glaspy JA, Economou JS Source: Journal of Clinical Oncology, 21(12), 2003, pg 2415-2432 This article reviews the immunologic basis of clinical trials that test the means of tumor antigen presentation, recognition...
Immunotherapy: past, present and future Author: Waldmann TA Source: Nature Medicine, 9(3), 2003, pg. 269 Active immunotherapy has been successful against infectious agents that cause self-limiting diseases. Effective immunotherapy for chronic diseases and cancer, however, will require...
Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus Author: Kass E, et al. Source: Cancer Research, 59, 1999, pg 676 Background CEA is expressed in normal epithelial tissue (along the GI tract and at times in the trachea and respiratory tree) as well as in a high percentage of colon,...
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule Authors: Horig H, et al. Source: Cancer Immunol Immunother 49, 2000, pg 504 Background Vaccination strategies for cancer treatment has been an idea for nearly a century, but without much success New understandings of immune function and...
Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinoma Authors: von Mehren M, et al. Source: Clinical Cancer Research, 6, 2000, pg 2219 Background The development of cancer vaccines has been attempted for over a century Recent developments have given insight into the immune response, paving...
When Will Melanoma Vaccines Be Proven Effective? Authors: Sosman JA, Weeraratna AT, Sondak VK Source: J Clin Oncol. 2004 Feb 1;22(3):387-9. Epub 2003 Dec 22 This article serves to update the reader on the current state of vaccines for the treatment of melanoma. In doing so, it highlights some...